Drug intelligence / Profile preview

Target Z inhibitor

Development stage: Preclinical
Lead developer: Txinno Bioscience
Modality: Small Molecules
Administration: Oral

Overview

Target Z inhibitor is a preclinical-stage small molecule being developed by Txinno Bioscience for the treatment of cancer. It is part of the company's tumor-extrinsic/immunotherapy portfolio, designed to modulate the tumor microenvironment by regulating the STING (Stimulator of Interferon Genes) signaling pathway. By targeting an undisclosed protein referred to as 'Target Z', the compound aims to enhance innate immunity-based anti-tumor responses. The program is currently in the Hit to Lead discovery phase and involves collaborations with several South Korean research and governmental partners, including the Korea Drug Development Fund (KDDF) and the Korea Research Institute of Chemical Technology (KRICT).

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on Target Z inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Target Z inhibitor.

Explore the full profile